Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.37 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.37 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.37 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28219425 | 0.85 | L3MBTL1 (0.59) | ESR1L3MBTL1ALDH1A1GAAPOLB | |
| SCHEMBL25575127 | 0.81 | GABBR2 (0.50) | ESR1ESR2L3MBTL1ALDH1A1GAA | |
| SCHEMBL5918571 | 0.81 | GABBR2 (0.50) | ESR1ESR2L3MBTL1ALDH1A1GAA | |
| SCHEMBL20342100 | 0.81 | GABBR2 (0.50) | ESR1ESR2L3MBTL1ALDH1A1GAA | |
| SCHEMBL25575108 | 0.80 | L3MBTL1 (0.49) | ESR1ESR2L3MBTL1ALDH1A1GAA | |
| SCHEMBL3274728 | 0.79 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1GAAPOLBTDP1 | |
| SCHEMBL5073702 | 0.78 | FFAR1 (0.57) | ESR1ESR2ALDH1A1POLBPTGS1 | |
| SCHEMBL5070991 | 0.78 | FFAR1 (0.57) | ESR1ESR2ALDH1A1POLBPTGS1 | |
| SCHEMBL5070994 | 0.78 | FFAR1 (0.57) | ESR1ESR2ALDH1A1POLBPTGS1 | |
| SCHEMBL5070310 | 0.75 | FFAR1 (0.58) | ESR1ESR2L3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265930-A4 | CYCLODEXTRIN DIMERS WITH SPACERS HAVING PEPTIDE STRUCTURES FOR ENCAPSULATION OF PHARMACEUTICALLY ACTIVE SUBSTANCES WITH POTENTIAL HIGH SIDE-EFFECTS | CERAMOPTEC GMBH (DE) | 2005-12-21 | — | — | EP | disclosed |
| US-6602988-B2 | Preselected enzyme cleavage points are stable in blood but are cleavable within cells; use in drug delivery such as of antitumor agents | CERAMOPTEC INDUSTRIES, INC. | 2003-08-05 | — | — | US | disclosed |
| EP-1265930-A1 | CYCLODEXTRIN DIMERS WITH SPACERS HAVING PEPTIDE STRUCTURES FOR ENCAPSULATION OF PHARMACEUTICALLY ACTIVE SUBSTANCES WITH POTENTIAL HIGH SIDE-EFFECTS | CeramOptec GmbH (DE) | 2002-12-18 | — | — | EP | disclosed |
| US-20020094950-A1 | Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects | BIOLITEC PHARMA MARKETING LTD. (MY) | 2002-07-18 | — | — | US | disclosed |
| WO-2001051524-A1 | CYCLODEXTRIN DIMERS WITH SPACERS HAVING PEPTIDE STRUCTURES FOR ENCAPSULATION OF PHARMACEUTICALLY ACTIVE SUBSTANCES WITH POTENTIAL HIGH SIDE-EFFECTS | CERAMOPTEC INDUSTRIES, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-0207437-B1 | NEW CARNITINE SALTS PARTICULARLY SUITABLE FOR ORAL USE | BIORESEARCH S.p.A. (IT) | 1988-08-24 | — | — | EP | disclosed |
| US-4673534-A | ALKYLSULFONATE SALTS, USEFUL IN TREATMENT OF MYOPATHY | BIORESEARCH SPA (IT) | 1987-06-16 | — | — | US | disclosed |
| EP-0207437-A1 | New Carnitine salts particularly suitable for oral use | BIORESEARCH S.p.A. (IT) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094950-A1 | Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects | BTD, CD44, CD22 | ESR1 2248/4885ESR2 2751/4885L3MBTL1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.